Egypt Pharmaceuticals and Healthcare Report Q2 2016

93 pages report Published in
Pharmaceuticals
Publisher: Business Monitor International

arrowFor This Report

BMI View: Egypt’s evolving demographic and epidemiological profile will support pharmaceutical growth
over the long-term. The Egyptian government’s commitment to healthcare has been demonstrated through
significant increases to national budget allocations for the health sector. We note that the government is
demonstrating increasing will to implement policy reforms within the health sector, boosting Egypt’s
attractiveness to international pharmaceutical companies. However, questions regarding financial
feasibility will be raised. The country’s improving political outlook and gradual economic recovery, albeit a
slow one, will add to the market’s attractiveness; however, regional instabilities remain a deterrent to
company interest.
Headline Expenditure Projections
? Pharmaceuticals: EGP33.08bn (USD4.29bn) in 2015 to EGP36.48bn (USD4.47bn) in 2016; +10.3% in
local currency terms and 4.1% in US dollar terms. Forecast unchanged from Q116
? Healthcare: EGP114.20bn (USD14.83bn) in 2015 to EGP127.06bn (USD15.57bn) in 2016; +11.3% in
local currency terms and 5.0% in US dollar terms. Forecast upgraded from Q116.

Table of Contents

BMI Industry View 7
Table: Headline Pharmaceuticals & Healthcare Forecasts (Egypt 2014-2020) 7
SWOT 9
Industry Forecast 11
Pharmaceutical Market Forecast 11
Table: Pharmaceutical Sales, Historical Data And Forecasts (Egypt 2012-2020) 13
Healthcare Market Forecast 14
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Egypt 2012-2020) 16
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Egypt 2012-2020) 17
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Egypt 2012-2020) . 17
Prescription Drug Market Forecast 18
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Egypt 2012-2020) 19
Patented Drug Market Forecast 20
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Egypt 2012-2020) 21
Generic Drug Market Forecast 22
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Egypt 2012-2020) 24
OTC Market Forecast 25
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Egypt 2012-2020) 27
Pharmaceutical Trade Forecast 28
Table: Pharmaceutical Trade Data And Forecasts (Egypt 2014-2020) 30
Table: Pharmaceutical Trade Data And Forecasts local currency (Egypt 2014-2020) 31
Industry Risk Reward Index 32
Middle East and Africa Risk/Reward Index - Q2 2016 32
Egypt Risk/Reward Index 39
Rewards 39
Risks 40
Regulatory Review 41
Intellectual Property Issues 41
Pricing Regime 43
Reimbursement Regime 45
Market Overview 48
Healthcare Sector 49
Table: Healthcare Resources (Egypt 2010-2015) 53
Table: Healthcare Personnel (Egypt 2010-2015) 53
Table: Healthcare Activity (Egypt 2010-2015) 54
Research & Development 54
Clinical Trials 55
Epidemiology 56
Competitive Landscape 61
Research-Based Industry 61
Table: Multinational Market Activity 63
Generic Drugmakers 64
Pharmaceutical Distribution 65
Pharmaceutical Retail Sector 65
Company Profile 67
Amoun Pharmaceutical Company (APC) 67
Egyptian International Pharmaceutical Industries Co (EIPICO) 70
Medical Union Pharmaceuticals (MUP) 74
South Egyptian Drug Industries (SEDICO) 77
VACSERA 80
Demographic Forecast 82
Demographic Outlook 82
Table: Population Headline Indicators (Egypt 1990-2025) 83
Table: Key Population Ratios (Egypt 1990-2025) 83
Table: Urban/Rural Population & Life Expectancy (Egypt 1990-2025) 84
Table: Population By Age Group (Egypt 1990-2025) 84
Table: Population By Age Group % (Egypt 1990-2025) 85
Glossary 87
Methodology 89
Pharmaceutical Expenditure Forecast Model 89
Healthcare Expenditure Forecast Model 89
Notes On Methodology 90
Risk/Reward Index Methodology 91
Index Overview 92
Table: Pharmaceutical Risk/Reward Index Indicators 92
Indicator Weightings 93

List of Tables

Table: Headline Pharmaceuticals & Healthcare Forecasts (Egypt 2014-2020)
Table: Pharmaceutical Sales, Historical Data And Forecasts (Egypt 2012-2020)
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Egypt 2012-2020)
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Egypt 2012-2020)
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Egypt 2012-2020)
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Egypt 2012-2020)
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Egypt 2012-2020)
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Egypt 2012-2020)
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Egypt 2012-2020)
Table: Pharmaceutical Trade Data And Forecasts (Egypt 2014-2020)
Table: Pharmaceutical Trade Data And Forecasts local currency (Egypt 2014-2020)
Table: Healthcare Resources (Egypt 2010-2015)
Table: Healthcare Personnel (Egypt 2010-2015)
Table: Healthcare Activity (Egypt 2010-2015)
Table: Multinational Market Activity
Table: Population Headline Indicators (Egypt 1990-2025)
Table: Key Population Ratios (Egypt 1990-2025)
Table: Urban/Rural Population & Life Expectancy (Egypt 1990-2025)
Table: Population By Age Group (Egypt 1990-2025)
Table: Population By Age Group % (Egypt 1990-2025)
Table: Pharmaceutical Risk/Reward Index Indicators

Related Reports

  • Egypt Pharmaceuticals and Healthcare Report Q1 2016BMI View: Egypt's universal health coverage implementation will face delays in its roll-out given the government's poor track record of healthcare policy implementation. Questions regarding financial feasibility will also be raised; however, we note that the government is demonstrating increasing will to implement policy reforms within the sector, boosting Egypt's attractiveness to international pharmaceutical companies. Headline Expenditure Projections ? Pharmaceuticals: EGP29.50bn […]
  • Egypt Pharmaceuticals and Healthcare Report Q1 2015BMI View: Recent developments have led us to hold a more positive outlook for Egypt's pharmaceutical and healthcare markets. An increased healthcare budget for 2015, combined with the government's efforts at developing the local manufacturing industry and combating medicine shortages and counterfeit drugs are all positive developments. We expect Egypt's relative political stability and positive economic outlook to further increase interest from foreign pharmaceutical […]
  • Kuwait Pharmaceuticals and Healthcare Report Q1 2015BMI View: With some of the largest financial buffers of any GCC member nation, Kuwait is well equipped to insulate health expenditure from the near-term effects of falling oil prices. Accordingly, drugmakers can expect high and rising underlying demand for branded prescriptions to be well sustained, due to the sector's perception as a critical source of economic diversification away from hydrocarbons. However, recurrent government resignations and a recent stalemate between the […]
  • Kuwait Pharmaceuticals and Healthcare Report Q3 2015BMI View: While the losses incurred by Yiaco, the largest drug distributor in Kuwait, highlight a deteriorated near-term operating environment, with markedly lower prices as a result of the ongoing Gulf Cooperation Council (GCC) medicine price unification process, drugmakers will continue to perceive high long-run returns. Exhibiting a high and very costly burden of diabetes and cardiovascular conditions, Kuwait's aging population will continue to receive rising access to quality […]
  • Saudi Arabia Pharmaceuticals and Healthcare Report Q4 2014BMI View: Saudi Arabia's economic, demographic, epidemiological and political factors will shape the provision of healthcare across the nation. Healthcare spending will be greatly boosted by government initiatives. The new health projects will increase access to healthcare and provide revenue-earning opportunities for drugmakers, medical device companies and healthcare service providers. The government's planned privatisation of the healthcare industry will increase investment in the […]